Search Results - "Fort, J. G."

Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone by Goldstein, J. L., Hochberg, M. C., Fort, J. G., Zhang, Y., Hwang, C., Sostek, M.

“…Aliment Pharmacol Ther 2010; 32: 401–413 Summary Background  Gastroprotective co‐therapy may reduce the risk of nonsteroidal anti‐inflammatory drug…”
Get full text

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis by Pincus, T, Koch, G, Lei, H, Mangal, B, Sokka, T, Moskowitz, R, Wolfe, F, Gibofsky, A, Simon, L, Zlotnick, S, Fort, J G

“…Background: Acetaminophen (paracetamol) is recommended as the initial pharmacological treatment for knee or hip osteoarthritis. However, survey and clinical…”
Get full text

Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric‐coated aspirin 325 mg + immediate‐release omeprazole 40 mg) or enteric‐coated aspirin 325 mg + enteric‐coated omeprazole 40 mg – a randomised, phase 1, crossover study by Miner, P. B., Fort, J. G., Zhang, Y.

“…Summary Background Aspirin therapy is associated with adverse upper gastrointestinal effects. PA32540 is a coordinated‐delivery tablet containing…”
Get full text

Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy volunteers by Miner, P., Plachetka, J., Orlemans, E., Fort, J. G., Sostek, M.

“…Aliment Pharmacol Ther 2010; 32: 414–424 Summary Background  PN 400 is a fixed‐dose combination formulated to provide sequential delivery of immediate‐release…”
Get full text

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo by Goldstein, Jay L, Eisen, Glenn M, Lewis, Blair, Gralnek, Ian M, Zlotnick, Steve, Fort, John G

“…Data indicate that cyclooxygenase-2-specific inhibitors cause less gastroduodenal mucosal damage than nonspecific NSAIDS, but their effects on the small bowel…”
Get more information

Efficacy of Celecoxib in Treating Symptoms of Viral Pharyngitis: A Double-Blind, Randomized Study of Celecoxib versus Diclofenac by Weckx, LLM, Ruiz, JE, Duperly, J, Mendizabal, GA Martínez, Rausis, MBG, Piltcher, SL, Saffer, M, Matsuyama, C, Levy, S, Fort, JG

“…This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional non-steroidal anti-inflammatory drug…”
Get full text

Muscle involvement in polyarteritis nodosa: report of a patient presenting clinically as polymyositis and review of the literature by Fort, J G, Griffin, R, Tahmoush, A, Abruzzo, J L

“…Muscle symptoms, especially myalgias, appear to be common in patients with polyarteritis nodosa (PAN). We describe a patient who presented with a generalized…”
Get more information

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study by Singh, Gurkirpal, Fort, John G, Goldstein, Jay L, Levy, Roger A, Hanrahan, Patrick S, Bello, Alfonso E, Andrade-Ortega, Lilia, Wallemark, Carl, Agrawal, Naurang M, Eisen, Glenn M, Stenson, William F, Triadafilopoulos, George

“…To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among…”
Get more information

COX-2 Specific Inhibitors in the Management of Osteoarthritis of the Knee: A Placebo-Controlled, Randomized, Double-Blind Study by McKenna, Frank, Weaver, Arthur, Fiechtner, Justus J, Bello, Alfonso E, Fort, John G

“…COX-2 specific inhibitors have demonstrated significant safety advantages and comparable efficacy in osteoarthritis (OA) compared with conventional…”
Get full text

The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials by Boers, Maarten, Tangelder, Marco J D, van Ingen, Hein, Fort, John G, Goldstein, Jay L

“…The risk of major ulcer complications on treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is known to increase exponentially with age. However, in…”
Get full text

Mononuclear cell (MNC) subtypes in osteoarthritis synovial fluid. Comparison with MNC subtypes in rheumatoid arthritis synovial fluid by Fort, J G, Flanigan, M, Smith, J B

“…To examine mononuclear cell (MNC) subtypes in osteoarthritis (OA) synovial fluid (SF) and compare these results with MNC subtypes in SF from patients with…”
Get more information

Treatment of rheumatoid arthritis by immunization with mononuclear white blood cells: results of a preliminary trial by Smith, J B, Fort, J G

“…To determine if immunization with alloantigenic blood mononuclear cells (MNC) in active rheumatoid arthritis (RA) can result in objective and subjective…”
Get more information

Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis by Simon, Lee S., Zhao, Sean Z., Arguelles, Lester M., Lefkowith, James B., Dedhiya, Seema D., Fort, John G., Johnson, Kenneth E.

“…This study was conducted to compare the effect of etodolac, nabumetone, and oxaprozin use on gastrointestinal (GI) safety and associated costs based on…”
Get full text

Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee by Zhao, Sean Z., Dedhiya, Seema D., Bocanegra, Tomas S., Fort, John G., Kuss, Michael E., Rush, Susan M.

“…Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for the treatment of signs and symptoms of osteoarthritis (OA). Nabumetone and oxaprozin…”
Get full text

B cell surface marker analysis of synovial fluid cells in a patient with monoarthritis and chronic lymphocytic leukemia by Fort, J G, Fernandez, C, Jacobs, S R, Abruzzo, J L

“…We describe a women with clinically quiescent chronic lymphocytic leukemia who developed monoarthritis consistent with her known diagnosis of osteoarthritis…”
Get more information

Effective Treatment of Laparoscopic Cholecystectomy Pain with Intravenous Followed by Oral COX-2 Specific Inhibitor by Joshi, Girish P., Viscusi, Eugene R., Gan, Tong J., Minkowitz, Harold, Cippolle, Mark, Schuller, Rienhard, Cheung, Raymond Y., Fort, John G.

“…In this multicenter, double-blinded, randomized, placebo-controlled study we evaluated the analgesic and opioid-sparing efficacy of a preoperative dose of IV…”
Get full text

Abnormal T-cell function in patients with psoriatic arthritis : evidence for decreased interleukin 2 production by FORT, J. G, SMITH, J. B, ABRUZZO, J. L

“…Psoriatic arthritis (PSA) is an inflammatory arthritis associated with psoriasis. Although not considered an autoimmune process, there is evidence for humoral…”
Get full text

Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study by Raskin, J B, White, R H, Jaszewski, R, Korsten, M A, Schubert, T T, Fort, J G

“…To compare ranitidine to misoprostol with respect to the prevention of gastric and duodenal ulcers in patients on chronic NSAID therapy. A multi-center, 8-wk,…”
Get more information

Efficacy of Celecoxib, a COX-2–Specific Inhibitor, and Naproxen in the Management of Acute Ankle Sprain: Results of a Double-Blind, Randomized Controlled Trial by Petrella, Robert, Ekman, Evan F, Schuller, Reinhard, Fort, John G

“…OBJECTIVE:To assess the efficacy and safety of celecoxib and naproxen in the treatment of acute ankle sprain. DESIGN:Double-blind, parallel-group, randomized…”
Get full text

Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: Pooled analysis of 2 trials by GOLDSTEIN, Jay L, BELLO, Alfonso E, SPALDING, William, SUH, Sandy, FORT, John G

“…To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or…”
Get full text